Collaboration Agreement, Cost Splits Description

No definition available.

Name:	acad_CollaborationAgreementCostSplitsDescription
Namespace Prefix:	acad_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Collaborative Arrangements Upfront consideration and transaction Payment.

+ References

No definition available.

+ Details

Name:	acad_CollaborativeArrangementsUpfrontConsiderationAndTransactionPayment
Namespace Prefix:	acad_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Collaborative arrangements upfront license fee.

+ References

No definition available.

+ Details

Name:	acad_CollaborativeArrangementsUpfrontLicenseFee
Namespace Prefix:	acad_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Collaborative arrangements upfront payment.

+ References

No definition available.

+ Details

Name:	acad_CollaborativeArrangementsUpfrontPayment
Namespace Prefix:	acad_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

PRV liability

+ References

No definition available.

+ Details

Name:	acad_PrvLiability
Namespace Prefix:	acad_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Amount of contractual obligation, including, but not limited to, long-term debt, lease obligation, purchase obligation, and other commitments.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 942
-SubTopic 235
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S50
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.12-04(a))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3

+ Details

Name:	us-gaap_ContractualObligation
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Total loss recognized during the period from the impairment of goodwill plus the loss recognized in the period resulting from the impairment of the carrying amount of intangible assets, other than goodwill.

+ References

No definition available.

+ Details

Name:	us-gaap_GoodwillAndIntangibleAssetImpairment
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_OtherCommitmentsLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

The cash inflow from disposal of asset without physical form usually arising from contractual or other legal rights, excluding goodwill.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 230
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 12
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482740/230-10-45-12

+ Details

Name:	us-gaap_ProceedsFromSaleOfIntangibleAssets
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(17))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Name Accounting Standards Codification
-Section 45
-Paragraph 5
-SubTopic 210
-Topic 954
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477220/954-210-45-5

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 230
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 8
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482913/230-10-50-8

+ Details

Name:	us-gaap_RestrictedCashNoncurrent
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Details

Name:	us-gaap_CreditFacilityAxis=us-gaap_LetterOfCreditMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_OtherCommitmentsAxis=acad_CorporateCreditCardProgramMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_OtherCommitmentsAxis=acad_FleetProgramMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=acad_StokeTherapeuticsIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=acad_LicenseAgreementsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_StatementGeographicalAxis=srt_NorthAmericaMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=acad_NeurenPharmaceuticalsLimitedMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=acad_SanionaMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=acad_Nnz2591Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_BalanceSheetLocationAxis=acad_DevelopmentCommercializationAndSalesMilestonesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_RangeAxis=srt_MaximumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_BalanceSheetLocationAxis=us-gaap_SalesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Commitments and Contingencies - Additional Information (Detail) - USD ($) $ in Thousands		1 Months Ended			3 Months Ended		9 Months Ended		12 Months Ended
	Nov. 30, 2024	Jul. 31, 2023	Jan. 31, 2022	Aug. 31, 2018	Mar. 31, 2025	Sep. 30, 2018	Sep. 30, 2025	Sep. 30, 2023	Dec. 31, 2024	Sep. 30, 2024	Dec. 31, 2023
Other Commitments [Line Items]
Restricted cash							$ 9,471		$ 8,770	$ 8,770	$ 5,770
Letter of Credit \| Corporate Credit Card Program
Other Commitments [Line Items]
Restricted cash							5,000
Letter of Credit \| Fleet Program
Other Commitments [Line Items]
Restricted cash							400
Stoke Therapeutics, Inc. [Member]
Other Commitments [Line Items]
Milestone payments payable			$ 245,000
Stoke Therapeutics, Inc. [Member] \| Research and Development [Member]
Other Commitments [Line Items]
Upfront consideration and transaction costs			$ 60,000
Collaboration agreement description			Under the collaboration, the two companies will jointly share global research, development and commercialization responsibilities and share 50/50 in all worldwide costs and future profits with respect to a SYNGAP1 program
License Agreements [Member] \| North America
Other Commitments [Line Items]
Milestone payments payable							40,000
License Agreements [Member] \| Neuren Pharmaceuticals Limited [Member] \| North America
Other Commitments [Line Items]
Proceeds from Sale of Intangible Assets									146,500
Upfront payment		$ 100,000
Upfront license fee				$ 10,000
Milestone payment as intangible asset							40,000
PRV liability							29,600		$ 19,200
License Agreements [Member] \| Neuren Pharmaceuticals Limited [Member] \| Research and Development [Member] \| North America
Other Commitments [Line Items]
Upfront payment						$ 10,000		$ 100,000
License Agreements [Member] \| Saniona
Other Commitments [Line Items]
Upfront payment	$ 28,000
License Agreements [Member] \| Saniona \| Research and Development [Member]
Other Commitments [Line Items]
Upfront payment					$ 28,000
License Agreements [Member] \| NNZ-2591 [Member] \| Development Commercialization and Sales Milestones
Other Commitments [Line Items]
Milestone payments payable		831,300
Maximum
Other Commitments [Line Items]
Milestone payments payable							$ 3,500,000
Maximum \| License Agreements [Member] \| Neuren Pharmaceuticals Limited [Member] \| North America
Other Commitments [Line Items]
Milestone payments payable		$ 426,300		$ 455,000
Maximum \| License Agreements [Member] \| Saniona
Other Commitments [Line Items]
Milestone payments payable	582,000
Maximum \| License Agreements [Member] \| Saniona \| Development Commercialization and Sales Milestones
Other Commitments [Line Items]
Milestone payments payable	147,000
Maximum \| License Agreements [Member] \| Saniona \| Sales
Other Commitments [Line Items]
Milestone payments payable	$ 435,000